BITT focuses on developing clinical-stage TNFSR antagonist antibodies. Credit: PeopleImages.com – Yuri A/Shutterstock.

Boston Immune Technologies and Therapeutics (BITT) has received a $4m award from the National Institutes of Health/National Cancer Institute to support its ongoing Phase I clinical trial of its lead tumour necrosis factor superfamily receptor (TNFSR) antagonist.

This funding marks a significant milestone in the development of new treatments for cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BITT focuses on developing clinical-stage TNFSR antagonist antibodies.

The company also entered a sponsored research and exclusivity agreement with the McQuade Center for Strategic Research and Development (MSRD).

MSRD is a member of the worldwide Otsuka family of pharmaceutical companies.

See Also:

Under this agreement, MSRD will finance essential non-human primate studies for the pre-clinical development of BITT’s CD40 antagonist.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BITT CEO and co-founder Russell LaMontagne said: “Our agreement with Otsuka will provide significant resources in furtherance of our goal of filing an IND related to our CD40 antagonist programme in 2025.

“This is our second NIH/NCI grant to support our TNFR2 oncology programme and confirm the novelty of our antibody and the potential of TNFR2 as a therapeutic target.”

In August 2023, BITT received funding from the NIH to aid the preclinical development of its CD40 antagonist antibody.

The award for ‘Advancing BITT-101: A Novel Dominant CD40 Antagonist for Use in the Treatment of Sjögren’s Syndrome’ will help the company support steps toward filing an investigational new drug application (IND) this year.

Based in the US, BITT is pioneering a new class of antagonist antibodies targeting TNF superfamily receptors.

These are designed for applications in oncology, inflammation, autoimmunity, and infectious disease, leveraging the company’s proprietary DOMab platform.

The clinical trials for BIR2101, a monoclonal antibody targeting TNFR2, are currently underway.